1. Home
  2. IQ vs ABUS Comparison

IQ vs ABUS Comparison

Compare IQ & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iQIYI Inc.

IQ

iQIYI Inc.

HOLD

Current Price

$1.01

Market Cap

1.0B

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.48

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IQ
ABUS
Founded
2009
2005
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
839.5M
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
IQ
ABUS
Price
$1.01
$4.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$2.91
$5.00
AVG Volume (30 Days)
5.5M
1.8M
Earning Date
05-18-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$0.28
N/A
Revenue Next Year
$3.54
$239.71
P/E Ratio
N/A
$5.20
Revenue Growth
N/A
128.21
52 Week Low
$0.98
$3.04
52 Week High
$2.76
$5.10

Technical Indicators

Market Signals
Indicator
IQ
ABUS
Relative Strength Index (RSI) 33.62 55.54
Support Level $0.98 $4.15
Resistance Level $1.19 $4.60
Average True Range (ATR) 0.04 0.16
MACD 0.00 0.02
Stochastic Oscillator 20.89 58.31

Price Performance

Historical Comparison
IQ
ABUS

About IQ iQIYI Inc.

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: